内乳淋巴结照射(IMNI)改善临床II-III期乳腺癌术前全身治疗后的生存结局
研究纳入2005年8月至2013年12月497例临床II-III期乳腺癌患者,均接受蒽环类或紫杉类术前全身治疗、手术及术后放疗,其中IMNI组236例、非IMNI组261例。中位随访64个月,倾向性评分匹配后IMNI组5年无病生存率76.8% vs 非IMNI组63.4%(P=0.030),5年总生存率88.9% vs 84.1%(P=0.083)。结论认为IMNI改善生存结局,但需进一步前瞻性研究。
要点
- 匹配前IMNI组5年DFS 73.7% vs 非IMNI组71.5%,5年OS 86.3% vs 86.7%,均无显著差异(P>.05)。
- 倾向性评分匹配后IMNI组5年DFS 76.8% vs 非IMNI组63.4%(P=.030),5年OS 88.9% vs 84.1%(P=.083)。
- 匹配后多因素分析显示IMNI为DFS(P=.014)和OS(P=.047)的独立预后因素。
核心结论
- IMNI改善临床II-III期乳腺癌患者术前全身治疗后的生存结局。
- 需要进一步前瞻性研究来确定IMNI在术前全身治疗背景下的作用。
研究设计与样本
- 研究纳入2005年8月至2013年12月497例临床II-III期乳腺癌患者,均接受蒽环类或紫杉类术前全身治疗、手术及术后放疗。
- 放疗剂量为中位50 Gy(范围46-60 Gy),分25次,照射胸壁或乳腺,IMNI组236例、非IMNI组261例。
- 采用Kaplan-Meier法和log-rank检验评估无病生存(DFS)和总生存(OS),并进行倾向性评分匹配及单因素和多因素分析。
主要发现
- 中位随访64个月,IMNI组临床T分期更晚、病理N分期更晚、脉管侵犯阳性及内科或中央位置病变更多(P<.05)。
- 匹配前IMNI组5年DFS 73.7% vs 非IMNI组71.5%,5年OS 86.3% vs 86.7%,均无显著差异(P>.05)。
- 多因素分析显示IMNI为DFS的独立预后因素(P=.018),OS改善为临界意义(P=.067)。
- 倾向性评分匹配后IMNI组5年DFS 76.8% vs 非IMNI组63.4%(P=.030),5年OS 88.9% vs 84.1%(P=.083)。
- 匹配后多因素分析显示IMNI为DFS(P=.014)和OS(P=.047)的独立预后因素。
临床怎么用
- 作者认为IMNI改善临床II-III期乳腺癌患者术前全身治疗后的生存结局,需进一步前瞻性研究确定其作用。
局限性
- 需要进一步前瞻性研究来确定IMNI在术前全身治疗背景下的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The indication for internal mammary node irradiation (IMNI) after preoperative systemic therapy in breast cancer remains vague. This study was designed to evaluate the effect of IMNI in patients with clinical stage II-III breast cancer after preoperative systemic therapy and surgery. METHODS AND MATERIALS: Between August 2005 and December 2013, 497 patients with clinical stage II-III breast cancer underwent anthracycline- or taxane-based preoperative systemic therapy, surgery, and postoperative radiation therapy. A median dose of 50 Gy (range, 46-60 Gy) in 25 fractions was delivered to the chest wall or breast with IMNI (n = 236) or without IMNI (n = 261). Disease-free survival (DFS) and overall survival (OS) rates with or without IMNI were evaluated using the Kaplan-Meier method and compared with the log-rank test. Propensity score matching was performed to adjust for the unbalanced characteristics between the 2 groups. Prognostic factors associated with survival were evaluated by univariate and multivariate analysis. RESULTS: The median follow-up time was 64 months. Patients with IMNI presented with more advanced clinical T stage, pathologic N stage, positive lymph-vascular invasion, and medically or centrally located disease (P < .05). The 5-year DFS and OS rates were 73.7% and 86.3% in the IMNI group and 71.5% and 86.7% in the non-IMNI group, respectively (P > .05). Multivariate analysis demonstrated that IMNI was an independent prognostic factor for DFS (P = .018) and resulted in a borderline improvement in OS (P = .067). After propensity score matching, characteristics were well balanced. The 5-year DFS rates of IMNI and non-IMNI group were 76.8% and 63.4%, respectively (P = .030), and the 5-year OS rates were 88.9% and 84.1%, respectively (P = .083). IMNI was independently prognostic for DFS (P = .014) and OS (P = .047) in matched patients. CONCLUSIONS: IMNI improves survival outcomes in patients with clinical stage II-III breast cancer after preoperative systemic therapy. Further prospective studies are warranted to identify the role of IMNI in the preoperative systemic therapy setting.
引用
- Luo J, Jin K, Chen X, et al. Internal Mammary Node Irradiation (IMNI) Improves Survival Outcome for Patients With Clinical Stage II-III Breast Cancer After Preoperative Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30439485. doi:10.1016/j.ijrobp.2018.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。